SCHEMBL30412808

SCHEMBL30412808

NC(=O)c1csc(-c2nc(Nc3cc4c(cc3C3CC3)CNCC4)ncc2C(F)(F)F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 8/20 0.40
▸ MAP4K1 Q92918 1/20 0.39
▸ FLT4 P35916 4/20 0.37
▸ LRRK2 Q5S007 2/20 0.36
▸ CDK2 P24941 2/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CCNK O75909 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ CDK12 Q9NYV4 1/20 0.34
▸ FLT3 P36888 3/20 0.34
▸ KIT P10721 2/20 0.34
▸ JAK3 P52333 3/20 0.34
▸ SYK P43405 1/20 0.34
▸ LCK P06239 2/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ PLK1 P53350 1/20 0.33
▸ CCNA1 P78396 1/20 0.33
▸ PLK3 Q9H4B4 1/20 0.33
▸ PLK2 Q9NYY3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25204627 1.00 PTK2 (0.40) PTK2MAP4K1FLT4LRRK2CDK2
SCHEMBL25208797 0.88 MAP4K1 (0.45) PTK2MAP4K1FLT4LRRK2CDK2
SCHEMBL30411926 0.88 MAP4K1 (0.45) PTK2MAP4K1FLT4LRRK2CDK2
SCHEMBL30411397 0.87 PTK2 (0.44) PTK2MAP4K1FLT4CDK2CCNA2
SCHEMBL25199604 0.87 PTK2 (0.44) PTK2MAP4K1FLT4CDK2CCNA2
SCHEMBL25203333 0.85 PTK2 (0.42) PTK2MAP4K1FLT4LRRK2CDK2
SCHEMBL30412712 0.85 PTK2 (0.42) PTK2MAP4K1FLT4LRRK2CDK2
SCHEMBL25226866 0.85 MAP4K1 (0.48) PTK2MAP4K1
SCHEMBL30412433 0.85 MAP4K1 (0.48) PTK2MAP4K1
SCHEMBL25229641 0.85 MAP4K1 (0.40) PTK2MAP4K1LRRK2CDK2CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 — — US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 — — EP disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 PTK2 1123/4885MAP4K1 182/4885FLT4 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback